Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johnson, A.
Right arrow Articles by Anderson, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, A.
Right arrow Articles by Anderson, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:789-794, 1995
© 1995 European Society for Medical Oncology

research-article

Incidence and prognostic significance of t(14; 18) translocation in follicle center cell lymphoma of low and high grade

A report from southern Sweden

A. Johnson1,4, A. Brumn1, M. Dictor2, E. Rambech2, M. Akerman2 and H. Anderson3

1Departments ofOncology
2Pathology
3Southern Swedish Regional Tumor Registry, University Hospital Lund, Sweden

4Correspondence to: Dr. Anna Johnson Department of Oncology University Hospital S-221 85 Lund Sweden

Background: The t(14; 18)(q21;q32) is the most common recurrent genetic defect in follicle center cell lymphoma (FCC). Conflicting reports exist in regard to a possible prognostic significance for the translocation

Patients and methods: In a single center, 102 patients with either low-grade (n=50) or high-grade (n=52) FCC (Kiel classification) and a median follow-up of 82 months were retrospectively studied to determine survival in relation to t(14; 18) as shown by either PCR of the bcl-2 rearrangement in paraffinized tissue or karyotype analysis

Results: t(14; 18) was detected in 30 of 50 (60%) low-grade FCC and in 12 of 52 (23%) high-grade FCC. The presence of the t(14; 18) was not related to morphologic bone marrow involvement or other clinical parameters, but it was related to age: in low-grade FCC, patients with t(14; 18) were an average of 17 years younger (p = 0.002) than those without the translocation In the group with high-grade histology, 30% survived beyond 60 months regardless of t(14;18) status (p = 0.92). Patients with low-grade histology and t(14; 18) fared better than those without, irrespective of age (p = 0.01). No significant difference in disease-free survival related to t(14;18) was found in either low- or high-grade FCC

Conclusions: The incidence of t(14; 18) is in accord with that of other European reports. T(14;18) does not define a prognostic subset of high-grade FCC, but is significantly correlated with a better survival in low-grade FCC. The association of t (14; 18) with younger age and indolent lymphoma is perplexing in light of recent findings of an age-related increase in t (14; 18) in normal subjects

bcl-2 rearrangement, follicle center cell lymphoma, histopathologic grade, prognosis, t(14; 18) translocation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
D. J. Wallace, D. Shen, G. F. Reed, M. Miyanaga, M. Mochizuki, H. N. Sen, S. S. Dahr, R. R. Buggage, R. B. Nussenblatt, and C.-C. Chan
Detection of the bcl-2 t(14;18) Translocation and Proto-Oncogene Expression in Primary Intraocular Lymphoma.
Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2750 - 2756.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Farinha, H. Masoudi, B. F. Skinnider, K. Shumansky, J. J. Spinelli, K. Gill, R. Klasa, N. Voss, J. M. Connors, and R. D. Gascoyne
Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
Blood, September 15, 2005; 106(6): 2169 - 2174.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Fernandez-Ruiz, M. Cabrerizo, M. Ortega, C. Blas, P. Llamas, M. Santos-Roncero, S. Nieto, A. Acevedo, G. Perez, C. Nicolas, et al.
High Molecular Response Rate and Clinical Correlation in Patients with Follicular Lymphoma Treated with Cyclophosphamide-Vincristine-Prednisone plus Interferon {alpha} 2b
Clin. Cancer Res., July 1, 2003; 9(7): 2497 - 2503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. J. Biagi and J. F. Seymour
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation
Blood, May 29, 2002; 99(12): 4265 - 4275.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Lopez-Guillermo, F. Cabanillas, T. I. McDonnell, P. McLaughlin, T. Smith, W. Pugh, F. Hagemeister, M. A. Rodriguez, J. E. Romaguera, A. Younes, et al.
Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma
Blood, May 1, 1999; 93(9): 3081 - 3087.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. D. Gascoyne, S. A. Adomat, S. Krajewski, M. Krajewska, D. E. Horsman, A. W. Tolcher, S. E. O'Reilly, P. Hoskins, A. J. Coldman, J. C. Reed, et al.
Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma
Blood, July 1, 1997; 90(1): 244 - 251.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.